Comparative Pharmacology
Head-to-head clinical analysis: GONITRO versus NITROSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONITRO versus NITROSTAT.
GONITRO vs NITROSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.
None Documented
None Documented
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
2–3 minutes for initial distribution phase; terminal elimination half-life is approximately 1–4 minutes. Rapid clearance due to extensive metabolism in the liver and other tissues (via glutathione-organic nitrate reductase).
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Renal excretion of inactive metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for about 35%. Unchanged nitroglycerin is minimally excreted in urine (<1%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator